Full Press Release Details
CORPORATION ANNOUNCES ADJOURNMENT OF ANNUAL MEETING
Quorum Has Been Achieved to Reconvene Annual Meeting on Thursday June 10, 2021
Remain Open, Shareholders are Urged to Vote
N.J., June 7 2021 - Celsion Corporation (NASDAQ: CLSN), a clinical-stage development company focused on DNA-based immunotherapy
and next-generation vaccines, announced that its 2021 Annual Meeting of Stockholders, originally scheduled for Friday, June 4, 2021 at
10:00 a.m., and adjourned to Friday, June 4, 2021 at 4:00 p.m., was convened and adjourned without any business being conducted due to
a quorum not being present to conduct the meeting.
Annual Meeting has been adjourned to 10:00 a.m. ET on Thursday, June 10, 2021. The Company has obtained a quorum to conduct business
at the reconvened meeting. Stockholders will be able to attend the reconvened Annual Meeting virtually at www.virtualshareholdermeeting.com/CLSN2021.
record date for determining stockholders eligible to vote on proposals at the reconvened Annual Meeting remains April 5, 2021.
is a fully integrated, clinical stage biotechnology company focused on advancing a portfolio of innovative cancer treatments, including
immunotherapies and DNA-based therapies; and a platform for the development of nucleic acid vaccines currently focused on SARS-CoV2.
The company's product pipeline includes GEN-1, a DNA-based immunotherapy for the localized treatment of ovarian cancer. ThermoDox ,
a proprietary heat-activated liposomal encapsulation of doxorubicin, is under investigator-sponsored development for several cancer indications.
Celsion also has two platform technologies for the development of novel nucleic acid-based immunotherapies and other anti-cancer DNA
or RNA therapies. Both are novel synthetic, non-viral vectors with demonstrated capability in nucleic acid cellular transfection. For
more information on Celsion, visit www.celsion.com.
statements in this news release are made pursuant to the "safe harbor" provisions of the Private Securities Litigation Reform
Act of 1995. Readers are cautioned that such forward-looking statements involve risks and uncertainties including, without limitation,
statements relating to the offering and the use of proceeds therefrom, unforeseen changes in the course of research and development activities
and in clinical trials; the uncertainties of and difficulties in analyzing interim clinical data, particularly in small subgroups that
are not statistically significant; FDA and regulatory uncertainties and risks; the significant expense, time and risk of failure of conducting
clinical trials; the need for Celsion to evaluate its future development plans; possible acquisitions or licenses of other technologies,
assets or businesses; possible actions by customers, suppliers, competitors or regulatory authorities; and other risks detailed from
time to time in the Celsion's periodic filings with the Securities and Exchange Commission. Celsion assumes no obligation to update
or supplement forward-looking statements that become untrue because of subsequent events, new information or otherwise.
Vice President and CFO